OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology
2024年6月4日 - 5:05AM
ビジネスワイヤ（英語）
Engineered chickens producing single domain
antibodies (sdAbs) provided the scientific foundation for OmnidAb™,
the Company’s novel transgenic chicken platform launched in 2023
that generates fully human and stabilized sdAbs
OmniAb, Inc. (NASDAQ: OABI) today announced the
publication of a peer-reviewed paper titled “Chickens with a
Truncated Light Chain Transgene Express Single-Domain H Chain-Only
Antibodies” in the Journal of Immunology demonstrating that
chickens can be genetically engineered to produce functional heavy
chain-only single-domain antibodies.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240603162111/en/
Image rendering of OmniAb’s OmnidAb™, a
stabilized fully human heavy chain only single domain antibody
(Graphic: Business Wire)
sdAbs are produced naturally by camelids and have gained
popularity as small, robust and highly modular building blocks for
antibody discovery. While most other vertebrates use the standard
heterodimeric IgG structure due to the pairing of heavy and light
chains and do not produce sdAb format immunoglobulins, OmniAb’s
scientific team led this study to investigate if chickens can
support an immune repertoire based upon a heavy chain-only
scaffold.
“Our team’s published data provided the foundational work
supporting the feasibility of the Company’s next-generation
transgenic chicken OmnidAb that produces fully human stabilized
sdAbs. Unique physical properties of sdAbs can be leveraged for
evolving fields of antibody discovery, including alternate routes
of administration, diagnostic applications and therapeutic
approaches that are being explored by many of our partners,” said
Matt Foehr, Chief Executive Officer of OmniAb. “We currently have
80 partners leveraging OmniAb’s various platform technologies and
accessing OmniAb antibodies, spanning major geographies and ranging
from multinational big pharmas to venture-backed startups and
leading academics.”
“Our truncated light chain chickens are designed to produce
heavy (H) chain-only antibodies by deleting the light (L) chain
variable region and maintaining only the constant region to serve
as a chaperone for antibody secretion from the cell. We confirmed
in this published study that the H chain variable region functions
autonomously as a single domain without further engineering,
producing sdAbs with favorable biophysical properties and antigen
recognition profiles,” said Philip Leighton, Ph.D., Fellow of
Molecular Biology of OmniAb. “Truncated L chain design successfully
supported sdAb development and expression in chickens, and we are
delighted that this work enabled the successful launch of
OmnidAb.”
This article is available in the Scientific Publications section
of OmniAb’s website.
About OmniAb®
OmniAb licenses cutting edge discovery research technology to
the pharmaceutical and biotech industry to enable the discovery of
next-generation therapeutics. Our technology platform creates and
screens diverse antibody repertoires and is designed to quickly
identify optimal antibodies and other target-binding proteins for
our partners’ drug development efforts. At the heart of the OmniAb
platform is something we call Biological Intelligence™ (BI), which
powers the immune systems of our proprietary, engineered transgenic
animals to create optimized antibody candidates for human
therapeutics.
We believe the OmniAb animals comprise the most diverse host
systems available in the industry. Our suite of technologies and
methods, including computational antigen design and immunization
methods, paired with high-throughput single B cell phenotypic
screening and mining of next-generation sequencing datasets with
custom algorithms, are used to identify fully-human antibodies with
exceptional performance and developability characteristics.
Our proprietary transgenic animals, including OmniRat®,
OmniChicken® and OmniMouse® have been genetically modified to
generate antibodies with human sequences to streamline the
development of human therapeutic candidates. OmniFlic® and
OmniClic® are fixed or common light-chain rats and chickens,
respectively, designed to facilitate the discovery of bispecific
antibodies. OmniTaur™ provides cow-inspired antibodies with unique
structural characteristics for challenging targets. OmnidAb™, is an
in vivo platform for the discovery of single domain antibodies
based upon a human VH scaffold that affinity matures in a chicken
host environment to provide a functionally diverse immune
repertoire unavailable from mammalian systems. Our proprietary
technologies are joined with and leverage OmniDeep™, which is a
suite of in silico, AI and machine learning tools for therapeutic
discovery and optimization that are woven throughout our various
technologies and capabilities. Additionally, an established core
competency focused on ion channels and transporters further
differentiates OmniAb’s technology and creates opportunities in
many important and emerging target classes.
OmniAb technologies can be leveraged for the discovery of a
variety of next-generation antibody-based therapeutic modalities,
including bi- and multi-specific biologics, antibody-drug
conjugates, CAR-T therapies, targeted radiotherapeutics, and many
others.
For more information, please visit www.omniab.com.
Forward-Looking Statements
OmniAb cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. Words such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential” or continue” and similar expressions, are intended to
identify forward-looking statements. The forward-looking statements
are based on our current beliefs and expectations and include, but
are not limited to: the expected performance of our technologies;
their ability to create new discovery workflows; their impact on
our partners’ pipelines and products; and the high-affinity and
developability of resulting antibodies. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in our business, including, without
limitation: our future success is dependent on acceptance of our
technology platform and technologies by new and existing partners,
as well as on the eventual development, approval and
commercialization of products developed by our partners for which
we have no control over the development plan, regulatory strategy
or commercialization efforts; biopharmaceutical development is
inherently uncertain; risks arising from changes in technology; and
other risks described in our prior press releases and filings with
the SEC, including under the heading “Risk Factors” in the our
annual report on Form 10-K and any subsequent filings with the SEC.
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and we undertake no obligation to update such statements to reflect
events that occur or circumstances that exist after the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Partner Information
The information in this press release regarding partnered
products and programs comes from information publicly released by
our partners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240603162111/en/
OmniAb, Inc. Kurt Gustafson investors@OmniAb.com X (Twitter)
@OmniAbTech (510) 768-7760
OmniAb (NASDAQ:OABI)
過去 株価チャート
から 5 2024 まで 6 2024
OmniAb (NASDAQ:OABI)
過去 株価チャート
から 6 2023 まで 6 2024
